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Background: Use of strongly hypofractionated radiation treatments in dogs with intracranial
neoplasia did not improve outcomes and yielded increased rates of toxicosis.
Objectives: To evaluate safety and efficacy of a new, moderately hypofractionated radiation
protocol of 10 × 4 Gy compared to a standard protocol.
Animals: Convenience sample of 56 client-owned dogs with primary symptomatic brain tumors.
Methods: Retrospective observational study. Twenty-six dogs were assigned to the control
standard protocol of 20 × 2.5 Gy (group A) and 30 dogs to the new protocol of 10 × 4 Gy
(group B), assigned on owners' informed consent. Statistical analysis was conducted under the
“as treated” regime, using Kaplan-Meier and Cox-regression analysis. Treatment was delivered
with technically advanced image-guided radiation therapy. The 2 treatment groups were com-
pared in terms of outcome and signs of toxicosis.
Results: Overall progression-free interval (PFI) and overall survival (OS) time were favorable,
with 663 (95%CI: 497;828) and 637 (95%CI: 403;870) days, respectively. We found no signifi-
cant difference between the two groups: PFI for dogs in group A vs B was 608 (95%CI:
437;779) days and mean (median not reached) 863 (95%CI: 644;1083) days, respectively
(P = .89), and OS for dogs in group A vs B 610 (95%CI: 404;816) and mean (median not reached)
796 (95%CI: 586;1007) days (P = .83).
Conclusion and Clinical Importance: In conclusion, 10 × 4 Gy is a safe and efficient protocol for
treatment of primary intracranial neoplasia and future dose escalation can be considered.
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1 | INTRODUCTION
Definitive-intent radiation therapy for dogs with intracranial tumors
provides a long-term tumor control with a reasonably low risk of late
complications. In general, best survival outcomes involve radiation
protocols with relatively small fractions sizes of 2-3 Gy in 18-22 frac-
tions, to total doses of 45-54 Gy.1–3 With such protocols, outcome
has been attributed to be dependent on tumor size, but surprisingly
neither to location or presumed known tumor type.1–3
Abbreviations: 3DCRT, 3-dimensional conformal radiation therapy; BED, bio-
logically effective dose; CSF, cerebrospinal fluid; CT, computed tomography;
CTV, clinical target volume; GTV, gross tumor volume; IMRT, intensity-
modulated radiation therapy; NTCP, normal tissue complication probability;
MRI, magnetic resonance imaging; OAR, organ at risk; OS, overall survival; PFI,
progression-free interval; PTV, planning target volume; RT, radiation therapy
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Attempts to shorten radiation protocols for intracranial tumors in
dogs by reducing fraction number drastically, while maintaining an
adequate total dose, have been made but hypofractionated treat-
ments have not reached the same outcomes with median survival
times of only 1-1.5 years,4 compared to >2 years with more finely
fractionated protocols.1–3 Moreover, dogs treated with more coarsely
fractionated protocols (and often lower total doses) have increase in
toxicoses and impaired quality of life, especially when treated with
older techniques.5–8 Ideally, such a change in protocol maintains a
similar efficacy with no observable or only a slight increase in risk for
toxicosis. Late radiation toxicosis in the brain remains difficult to
detect with no consensus in medical literature as to which criteria
should be used. Diagnostic imaging after recurrence of signs of neuro-
logic disease provides some information as to whether worsening is
because of tumor progression or late radiation toxicosis.9–11 Conven-
tional diagnostic imaging modalities fail to reliably differentiate active
neoplastic tissue from radiation necrosis.9,12
In radiation therapy, the risk of toxicosis can be anticipated. In a
prior study, we calculated the normal tissue complication probability
(NTCP) with clinical data of former dogs with brain tumor with
10 × 4.35 Gy to be safe with a low risk of radiation-induced toxicosis
for most tumor sizes and locations, given an appropriate technical
radiation therapy standard. This protocol provides the same biologi-
cally effective dose (BED) as the routinely used 20 × 2.5 Gy protocol,
and should theoretically result in an equal tumor control.13
However, to implement such a new, moderately hypofractio-
nated, 10-fraction protocol into clinical practice, we used a conserva-
tive approach: instead of using 10 × 4.35 Gy, we started with a lower
dose protocol of 10 × 4 Gy. This protocol was calculated for having
the “same risk” (probability estimates of late toxicosis, eg, NTCP) and
hence a lower BED. As a consequence, the 10 × 4 Gy protocol was
expected to have a clinically detectable inferior outcome.
The aim of this clinical study was to provide data on clinical out-
come described as progression-free interval (PFI) and overall survival
(OS), as well as clinical performance and the occurrence of adverse
events in dogs with intracranial tumors irradiated with either
10 × 4 Gy or the traditional protocol of 20 × 2.5 Gy. We hypothe-
sized that a clinically detectable difference of outcome for PFI, OS
time or both between the 2 treatment groups should occur, because
of differences in the BED given. The resulting data will be used for
the future decision, whether clinical escalation of dose per fraction for
the irradiation in 10 fractions can be safely attempted.
2 | MATERIAL AND METHODS
2.1 | Study design
Retrospective observational study.
2.2 | Dog and tumor characteristics
Client-owned dogs diagnosed with symptomatic primary intracranial
tumors presented for radiotherapy at the Division of Radiation Oncol-
ogy, Vetsuisse Faculty, University Zurich, Switzerland, were enrolled in
the study. The intracranial tumors were diagnosed based on neurologic
examination including examination of cerebrospinal fluid (CSF)
and magnet resonance imaging (MRI) or computed tomography
(CT).10,11,14–17 Clinical data including signalment, tumor type based on
diagnostic imaging, tumor size and location, staging work-up, treatment
modality, treatment schedule and response, time to last follow-up, time
to progression, time to death, and cause of death were collected. All
symptomatic primary intracranial tumors were enrolled, including
pituitary tumors and no difference was made in terms of workup and
treatment recommendations. Workup included clinical and neurological
examination, complete blood count (CBC), biochemical profile, thoracic
radiographs or CT and further exams such as CSF analysis, if indicated
for the specific findings. Dogs with signs of neurologic disease at pre-
sentation were categorized into showing mild, moderate, or severe
signs.3 Seizures as a neurologic abnormality were recorded separately
as they were not included in this classification system.
2.3 | Treatment
Protocol choice was left to owner's decision and made by owner's
informed verbal or signed consent. Dogs were treated with either
20 × 2.5 Gy (group A) or 10 × 4 Gy (group B). However, most dogs
before 2015 were treated with a 20-fraction protocol, and the switch
to more 10-fraction treatments was made in May 2015. As similar
protocols have been published in the past and a risk estimate
existed,7,13 no formal ethics approval from the Animal Ethics Council
of the Canton of Zurich, Switzerland, was needed.
Radiation was delivered with a 6MV linear accelerator (Clinac iX,
Varian, Palo Alto, California) equipped with a 5-mm leaf-width multi-
leaf-collimator, using photons and 3-dimensional (3D) conformal radia-
tion therapy (3DCRT) or intensity-modulated radiation therapy (IMRT).
Treatment planning was performed using Eclipse External Beam
planning software (Eclipse treatment planning software, Varian Oncol-
ogy Systems, Palo Alto, California), applying AAA-algorithm (10.0.28).
Radiation was planned isocentrically, with heterogeneity correction,
by a board-certified radiation oncologist (CRB or VM). Planning-CT
and daily treatments were performed under general anesthesia in ster-
nal recumbency. Reproducible positioning was accomplished with
both an individually shaped vacuum cushion (BlueBag BodyFix, Elekta
AB, Stockholm, Sweden) and a custom-made bite block.18 Target vol-
umes and organs at risk (OAR) were contoured in a facility internal
standardized manner as previously published by our research team.13
In brief, the gross tumor volume (GTV) was delineated using coregis-
tered contrast-enhanced CT images or CT and MRI images, in tumors
with no contrast uptake T2 sequences were used for delineation of
GTV. Clinical target volume (CTV), accounting for subclinical micro-
scopic disease extension of 2-8 mm (presumed local infiltration,
according to tumor type) was defined. The CTV-margin was then
extended 3 dimensionally by 2 mm to define the planning target vol-
ume (PTV), accounting for setup uncertainties in daily image-guided
photon treatment. OAR were segmented as described previously.13
Additionally, for the assessment of radiation toxicosis, a volume
PTVbrain was computed, representing the portion of the PTV inside
the calvarium. Furthermore, the ratio of the target volume to the
entire brain volume (BV) was computed for each target volume.
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Accuracy of positioning in daily treatments was provided with on-
board imaging and daily orthogonal kilovolt-images. The recommenda-
tions for specifying dose and volumes were adhered to as proposed
by Keyerleber et al.,19 and in the ICRU reports 50 and 62 for 3DCRT
and ICRU report 83 for IMRT plans.20–22 The dose was prescribed at
the ICRU reference point, delivered in a protocol of either 10 × 4 Gy
(40 Gy total dose) or 20 × 2.5 Gy (50 Gy total dose). According to the
Swiss law and routine procedure in our clinic, a medical physicist
approved all treatment plans and the IMRT treatment plans were
dosimetrically verified before treatment using a phantom (Octavius-
Phantom, PTW Freiburg, Germany).
Treatment was delivered with definitive-intent, on a Monday to
Friday schedule.
Additional medical treatment before and after radiotherapy was
not standardized and adapted to the individual needs of the dogs.
Medication was usually started at the day of diagnosis or beginning of
signs of neurologic disease and adapted according to the improve-
ment clinical signs and consisted mostly of antiepileptic drugs and
corticosteroids.
2.4 | Follow-up
Dogs were invited for a clinical/neurologic examination 3 weeks after
radiotherapy to check for acute adverse effects and re-evaluation of
initial clinical and neurological abnormalities. Follow-up examinations
were recommended every 3 months for the 1st year after irradiation,
the interval was then prolonged to every 6 months. Dogs underwent
clinical and neurologic examination by a board-certified neurologist or
an experienced resident in veterinary neurology. Diagnostic MRI was
recommended at 6 and 12 months after irradiation. Further diagnos-
tics, for example, CBC, serum biochemistry, urinalysis, thoracic radio-
graphs, and ultrasonography examinations were not performed
routinely but based on the clinician's recommendations. Suspected
acute, early delayed, and late radiation toxicosis was based on the
VRTOG toxicity criteria and assessed on consensus among a board-
certified radiation oncologist (CRB, VM), neurologist, and radiologist
(RD).23 Suspected progressive disease was based on clinical and neu-
rological evaluation of the dog and also assessed on consensus among
a board-certified radiation oncologist (CRB, VM), neurologist, and
RD. In dogs with suspected progressive disease, diagnostic imaging
was recommended to confirm progressive disease.
Diagnostic imaging was mostly performed in-house in the Clinic
of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich, or at
the referring veterinarian's diagnostic imaging institute of choice.
Settings for diagnostic imaging performed at external facilities
were not standardized. Information for radiologic evaluation of dogs
was obtained from the original radiology report. In cases where the
radiology report did not contain all necessary information, a board-
certified RD reviewed all imaging studies of the corresponding dog.
Two-dimensional (2D) tumor measurements were obtained in OsiriX
(OsiriX, Version 4.0 64-bit, Pixmeo Sarl, Geneva, Switzerland). For 3D
tumor measurement, the control MRI studies were imported into
Eclipse External Beam planning software, contoured, and the resulting
tumor volumes were derived. For dogs that underwent follow-up
imaging, response to treatment was assessed according to the
response criteria as proposed by MacDonald.24
2.5 | Statistical analysis
Data were coded in excel and analyzed with SPSS (SPSS Version
24, IBM Corp., Armonk, New York). Descriptive statistics such as abso-
lute and relative frequencies as well as mean (median) and SD (IQR)
were computed. The nonparametric Mann-Whitney test investigated
differences in continuous variables with respect to a binary factor. The
Chi2 test was used to disclose associations between 2 discrete vari-
ables. In case of death clearly because of other cause (without signs of
disease progression), the dogs were censored at the time of death for
PFI analysis. Median survival time (OS) was defined as the interval
between the first radiation therapy until death. For OS, all deaths were
considered events and dogs that were still alive at the time of data eval-
uation or lost to follow-up were censored. Both OS time and PFI were
coded and analyzed with Kaplan-Meier accompanied by the log-rank
and Tarone-Ware tests and Cox-Regression (HR). Survival estimates
and median survival time were complemented with the corresponding
95% confidence intervals (95%CI). If not otherwise indicated, the statis-
tical analysis was conducted under the “as treated” regime. To adjust
the statistical analysis of most important outcomes for the nonrando-
mized study design, the “intention-to-treat” and “per-protocol” regimes
were applied assuming a cut-off in May 2015 (group A = treated before
cut-off, group B = treated after cut-off ). Results of statistical analyses
with P-value <.05 were considered statistically significant.
3 | RESULTS
3.1 | Dog and tumor characteristics
Of the 67 dogs presented for radiation therapy to the authors' institu-
tion in the relevant period between January 2012 and June 2017,
56 dogs (84%) met the inclusion criteria for the study: 30 were male
(19 neutered) and 26 were female (19 spayed). A total of 35 pure
(n = 24) and mixed (n = 11) breeds were represented, the most com-
mon being Boxer (n = 6), Golden Retriever (n = 5), and Labrador
Retriever (n = 4). Age ranged from 1.5 to 14 years with a mean of 9.0
(2.9) years, and weight ranged from 2.9 to 41.7 kg with a mean of
21.0 (11.8) kg. Dogs with signs of neurologic disease at the time of
presentation were judged as exhibiting mild (n = 27), moderate
(n = 20), or severe signs (n = 9). Twenty-four dogs were presented
with a history of seizure and 11/24 dogs showed seizure as their only
sign of neurologic disease. Tumors were radiologically diagnosed as
meningioma (n = 31, group A = 17, group B = 14), glioma (n = 12,
group A = 6, group B = 6), pituitary gland tumor (n = 10, group A = 1,
group B = 9), peripheral nerve sheath tumor (n = 2, group A only) and
choroid plexus tumor (n = 1, group B only). Distribution of tumor
types was significantly different between the groups when comparing
all tumor types (P = .021). The analysis was repeated with tumor types
occurring in both treatment groups only, however, group distribution
was still different (P = .028). Mean GTV was 2.76 cm3 (95%CI:
2.17;3.34) corresponding to a mean GTV/BV-ratio of 3.32% (95%CI:
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2.60;4.03). Mean CTV was 5.67 cm3 (95%CI: 4.40;6.54) correspond-
ing to a mean a CTV/BV-ratio of 6.54% (95%CI: 5.26;7.83). Mean
PTVbrain was 7.01 cm
3 (95%CI: 5.80;8.23), corresponding to a mean
PTVbrain/BV-ratio of 8.47% (95%CI: 6.93;10.00). A significant differ-
ence in sizes between the 2 treatment groups was noted only in CTV
(P = .010) but not in CTV/BV-ratio or any other target volume charac-
teristics. Twenty-seven tumors were located in the rostral cranial
fossa, 19 in the middle fossa, and 10 in the caudal fossa and there was
no significant difference between the 2 treatment groups. In 9 dogs,
only CT images were available for diagnosis and delineation of target
volumes and OAR. Of these dogs, 4/9 (44%) were diagnosed with
meningioma, 1/9 (11%) with a glioma and 4/9 (44%) with pituitary
gland tumors.
Three dogs had a surgical biopsy/debulking surgery before
radiotherapy, all 3 dogs were diagnosed with a meningioma and
surgery (leaving macroscopic tumor behind) was performed 23, 29,
and 70 days before radiotherapy.
3.2 | Treatment
Of the 56 dogs, 26 (46%) were treated with 20 × 2.5 Gy (group A),
20/26 (77%) were treated before the cut-off of May 2015, 6/26
(23%) were treated thereafter and 30 (54%) were treated with
10 × 4 Gy (group B), 2/30 (7%) were treated before the cut-off of
May 2015, 28/30 (93%) were treated thereafter. Forty of 56 dogs
(71%) were treated with a conformal photon plan (3DCRT) and 16/56
(29%) with an IMRT (sliding window). A median of 3 fields was used
(range 2-5, 2-4 for 3D-CRT, and 5 for IMRT). Of all treated dogs,
43/56 (77%) received corticosteroids at the first fraction with the
mean dose being 0.70 mg/kg (95%CI: 0.62;0.78). Corticosteroids
were reduced in 84% (36/43) dogs during radiotherapy by a mean of
54% (95%CI: 47;62) and could be stopped in 10 dogs after 3 weeks, in
7 dogs after 3 months, in 7 dogs after 6 months, in 1 dog after
9 months, and in 1 dog after 12 months, 13/56 (23%) dogs did not
receive corticosteroids. In 1 dog, steroid dose had to be increased dur-
ing radiation therapy because of insufficient improvement of signs of
neurologic disease. Corticosteroid doses and dose reductions were
not significantly different between the 2 treatment groups. Twenty-
seven of the dogs (48%) received antiepileptic treatment consisting of
either phenobarbital (n = 18) in a dose range of 1.4-3.1 mg/kg q12h
with a mean of 2.28 mg/kg (95%CI: 2.02;2.56) or levetiracetam
(n = 8) in a dose range of 13.2-33 mg/kg q8h with a mean of
21.25 mg/kg (95%CI: 17.23;25.27). In general, phenobarbital dose
was titrated to the upper level of the recommended range (25-30 mg/
L)25 and levetiracetam was added if seizure control was not complete,
or if dogs had adverse effects from phenobarbital. Thirty-four dogs
(61%) received other supportive medication as follows: gastric acid
inhibitors (n = 14), antiemetics (n = 6), antibiotics (n = 9), pain killers
(n = 3), antiarrhythmic drugs (n = 2), levothyroxine (n = 2) diphenhy-
dramine (n = 1), oclacitinib (n = 1), and different topical eye medica-
tion (n = 9).
Acute radiation toxicosis was assessed in all 56 dogs, 54/56 dogs
(96%) were assessed for early delayed and 47/56 dogs (84%) for late
radiation toxicosis. The dogs not assessed for early delayed or late
radiation toxicosis did not live long enough for assessment. None of
the dogs showed acute radiation toxicosis. In 1 dog, each (1/54, 1.9%
and 1/47, 2.1%) early delayed (steroid responsive and self-limiting)
and late radiation toxicosis was suspected.
3.3 | Follow-up and outcome
Clinical and neurological response at 6 months after radiotherapy was
assessed in 45/56 cases (80%; 21/26 from group A and 24/30 from
group B) and not significantly different between the groups (P = .67):
In group A, 19/21 showed improvement in clinical and neurological
response, and in group B, an improvement in clinical and neurological
response was documented in 20/24 dogs. The other 11 dogs (20%)
had died before they reached 6 months follow-up (5/11 from group A
and 6/11 from group B). Of these 11 dogs, death was attributed to
the brain tumor in 10 cases, 1/11 dogs (group A) died of tumor unre-
lated causes. Of the dogs that died before they reached 6 months
follow-up, 4/11 showed improvement of signs of neurologic disease
by the first control examination after radiotherapy, 5/11 showed sta-
ble signs of neurologic disease, and only 2/11 did not show improve-
ment of signs of neurologic disease. Eight dogs in group A and 5 dogs
in group B had seizures as their only presenting sign. About 7/8 dogs
(88%) in group A and 4/5 (80%) in group B had improved seizure con-
trol with no or only sporadic (<1/month) seizures after therapy, but it
is not possible to determine, whether seizure control was because of
tumor reduction or antiepileptic medication.
A total of 23 diagnostic imaging control examinations from
19 dogs were available for assessment according to the MacDonald
response criteria.24 Fifteen studies were performed up to 6 months
(mean 163 days; 47.9 days, range 86-219 days), 6 around the
recommended 1 year (mean 363 days; 96.9 days, range
236-496 days), and 2 at a later time point (538 and 895 days).
Response to treatment classified according to the MacDonalds
response criteria was complete remission in 2/23, partial remission in
7/23, stable disease in 10/23 and progressive disease (PD) in 4/23.
Median reduction in sum-product of longest diameters was 35%
(95%CI: 28;61). Median volumetric tumor reduction was 43% (95%CI:
37;67). The differences in 2D and 3D tumor reductions were not
significant between groups A and B (P = .56 for 2D, P = .88 for 3D-
reductions).
Two dogs with suspected glioma had to be excluded from
comparison of 2D and 3D measurements because of a lack of contrast
uptake of the brain lesion.
The mean follow-up was at 491 days, median at 483 days (95%
CI: 281;686 days). During this time, 27 dogs were clinically classified
as progressive. The median PFI for all cases was 663 days (95%CI:
497;828). We found no significant difference between the two
groups: PFI for dogs in group A vs group B was 608 (95%CI: 437;779)
days and mean (median not reached) 863 (95%CI: 644;1083) days
respectively (P = .89). The proportion of dogs free of progression at
1 and 2 years were 83% (95%CI: 67;99) and 34% (95%CI: 14;54) for
group A and 80% (95%CI: 66;94) and 60% (95%CI: 34;86) for group B
(Figure 1). Tumor type was a significant factor for outcome occurring
in both groups (P = .001) and direct comparison revealed significantly
shorter PFI for gliomas compared to meningiomas (P < .001) with
224 days (95%CI: 0;548) and 882 days (95%CI: 589;1175),
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respectively (Figure 2). Hence, for tumors radiologically diagnosed as
gliomas, PFI was 658 days shorter (95%CI: 257;1059) than for menin-
giomas. Also, dogs with severe signs of neurologic disease had a sig-
nificantly shorter PFI than dogs with mild signs (P = .008): PFI was
286 days shorter (95%CI: −107;679) in cases with severe signs of
neurologic disease compared to mild signs.
Median OS was 637 days (95%CI: 403;870; Figure 3). OS in
group A was 610 days (95%CI: 404;816) and was not reached in
group B, (mean OS 796 [95%CI: 585;1007] days; P = .83). The propor-
tion of dogs alive at 1 and 2 years was 77% (95%CI: 61;93) and 45%
(95%CI: 25;65) for group A, and 63% (95%CI: 43;83) and 57% (95%CI:
37;77) for group B. Tumor type as well as tumor and treatment vol-
umes in relation to the BV were significant prognostic factors for sur-
vival. Median survival time was significantly shorter (P < .001) for
dogs with radiological diagnosis of glioma than meningioma, with
226 days (95%CI: 109;343) and 811 days (95%CI: 694;928). Also con-
cerning survival time, tumors radiologically diagnosed as gliomas had a
585 days shorter OS (95%CI: 336;833) than tumors diagnosed as
meningiomas.
Of the 33 animals (59%) documented to have died, 22/26 dogs
were from group A, and 12/30 dogs were from group B; 22/33 (67%)
died of tumor (or potentially treatment)-related causes, all of them
showed worsening signs of neurologic disease and progression of
clinical signs identical to the initial presentation. Of these dogs, 11/22
(50%) did not have imaging confirmation; therefore, late radiation tox-
icosis could not be entirely ruled out but seemed unlikely based on
the clinical assessment. Death of tumor unrelated causes occurred in
11/33 cases (33%), these animals died of development of other
neoplastic diseases (n = 5), multiorgan failure (n = 4), other not tumor
related neurologic conditions (n = 2).
Survival analysis and analysis of PFI for the groups split by “inten-
tion to treat” and “per protocol” did not show any relevant differences
to the analyses above for groups split by “as treated” factor.
4 | DISCUSSION
In this study, we chose a conservative approach for the 1st-time
application of this moderately hypofractionated 10-fraction protocol
in dogs. A short protocol with 10 fractions and the same risk for late
toxicosis (NTCP), based on mathematical calculations, was compared
to the standard 20-fraction protocol.13 Based on VRTOG clinical
observations, no increased occurrence of toxicosis was found. The
outcome, as well as the low occurrence of adverse events in dogs irra-
diated with this moderately hypofractionated protocol of 10 × 4 Gy
for their brain tumors was not different from the standard protocol
and can be summarized as favorable.
Prior protocols used for the treatment of intracranial tumors in
dogs using a lower fraction number raised the suspicion that OS was
compromised by fatal acute or late radiation complications in >16%.5,8
Overall, large fraction sizes chosen and applied with older 2D or
nonimage-guided 3D techniques cannot be recommended for safe
future use.6 For some tumor constellations with small tumor volumes
in nonsensitive areas, a reduction in fraction size can safely be per-
formed, given an appropriate technical radiation therapy standard.4,26
Furthermore, a new protocol with 10 fractions of 4.35 Gy has been
theoretically calculated in 64 dogs and suggested that it may be safe
to treat small to intermediate sized tumors that are neither located
near the optic chiasm nor at the brainstem with 10 daily fractions of
4.35 Gy.13
FIGURE 1 Proportion free of progression for the 2 treatment groups
(black line: 10 × 4 Gy, n = 30; gray line: 20 × 2.5 Gy, n = 26). Censor
marks: In case of death clearly because of other cause (without signs
of disease progression), the dogs were censored at the time of death
for progression-free interval analysis. The dotted lines mark 1 and
2 years. No significant difference between the 2 groups was
found (P = .860)
FIGURE 2 Proportion free of progression for dogs with meningiomas
(black line, n = 31) and gliomas (gray line, n = 12), imaging diagnosis.
Censor marks: In case of death clearly because of other cause
(without signs of disease progression), the dogs were censored at the
time of death for progression-free interval (PFI) analysis. The dotted
lines mark 1 and 2 years. PFI was significantly shorter for dogs
diagnosed with gliomas (P < .001)
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In the dogs that had imaging performed at progression of signs of
neurologic disease, these signs could be attributed to tumor progression
(local or locoregional) and based on diagnostic imaging, no late radiation
toxicosis was suspected. As the latency to occurrence of radiation
necrosis varies greatly, the low incidence might have been attributed to
the only intermediate OS of the dogs compared to toxicosis outcomes
observed in human patients. However, the incidence as well as the time
of occurrence of radiation necrosis increases with increasing BED.27
The incidence of radiation necrosis in the cerebrum is 4% for a BED
>85-120 Gy2 and increases to 17% for BED >155-190 Gy2 and 22%
for BED >190-225 Gy2.
27 Calculation of BED for the protocols used in
our study were on the lower end with 112.5 Gy2 in group A and
120 Gy2 in group B, reassuring the incidence of radiation necrosis is
probably ≤4%, but might occur in some cases.
Clinical improvement as well as PFI and OS was not significantly
different between the treatment groups, even if the lower BED in the
10-fraction protocol implies a lower efficacy and tumor control proba-
bility.13 The median PFI of 22 months (95%CI: 16;27) in this study as
well as the percentage of dogs free of progression at 1- and 2-years
(81% and 41%) are comparable with other studies, as their 1- and
2-year proportions free of progression lie within our 95%CI range.
Also, the OS with a median of 21 months in this study (95%CI: 13;29)
and the proportion alive at 1- and 2-years (70% and 47%), respec-
tively, is comparable to reported findings.1–3 The outcomes with the
new, 10-fraction protocol represent a novelty, because the relatively
lower total dose of this moderately hypofractionated protocol can
most likely safely be escalated (as well as the total dose of a protocol
with the more finely fractionated, 20 × 2.5 Gy fractions) if applied
with conformal, daily image-guided treatment.
The herein used moderately hypofractionated protocol differs
from the currently increasingly used extreme hypofractionated stereo-
tactic or radiosurgery treatments.4,26,28 These treatments are applied
in humans in situations of noninfiltrative tumors and volumes that do
not exceed defined sizes. The risk for complications in radiosurgery
increases rapidly when >5-10 cm3 of brain tissue receive >12 Gy.29 In
relation, 10 cm3 represent 0.7% of the human BV with an estimate of
10400 cm3. Brain tumors in dogs usually do not meet the criteria of
non-invasiveness and small size, in our study all of the dogs were trea-
ted with a PTV > 2.17% of the dog's BV. Consequently, such extreme
treatment protocols are feasible in only few, carefully selected dogs in
veterinary medicine. Volume recommendations for high doses per
fraction in veterinary medicine suggest a volume for normal brain tis-
sue at prescribed dose <1.1cm3 (corresponding about 1.26% under
the assumption of a median BV of 87.24 cm3 as commonly found in
dogs), in dogs treated with 3 × 8 Gy, to be safe in regards of compli-
cations to radiotherapy.4 However, the high occurrence of locally
invasive variants of meningioma, as well as the lack of confirmatory
biopsy verifying noninvasive nature of the tumors, limits the appropri-
ate use of extremely hypofractionated, stereotactic radiation therapy
to small-intermediate size benign trigeminal nerve sheath tumors and
(small) pituitary adenomas.
MRI control examinations showed marked regression of tumor
volume of 19%-100% at the primary irradiated site in all dogs. Reduc-
tion of tumor burden depended on the method of measurement.
Three-dimensional measurements resulted in a “greater reduction” of
tumor volume than comparing the sum product of largest diameters.
This effect occurs in human glioblastoma multiforme, suggesting 3D
measurements to be preferred for accurate response assessment after
radiotherapy.30,31 Furthermore, 2 dogs with suspected glioma had to
be excluded from comparison of 2D and 3D measurements, because
of a lack of contrast uptake of the brain lesion. MacDonald's response
criteria were published in 1990 for assessment of CT studies limiting
their use in MRI, which has since progressed to be modality of choice
in brain diagnostics.
We acknowledge the limitations of the results presented herein:
The first statistical limitation was the almost-randomized design of the
study impedes interpretation of the results. For statistical analysis, the
“as treated” regime was applied. In this regime, the dogs are assigned
to the actual treatment groups. The chronological switch from 1 proto-
col (group A) to another (group B) does not represent an approxima-
tion to randomization. Therefore, 2 additional “intention to treat” and
“per protocol” regimes for statistical analysis aimed at adjusting for
this difficulty. The “intention to treat” regime adjusts for the time cut-
off by allocating the dogs treated before the cut-off to the A and oth-
erwise to the B group independently of their actual treatment. In
contrast, the “per protocol” regime considers only dogs treated before
the cut-off as truly A-dogs and those treated after the cut-off as truly
B-dogs. Although, some dogs before May 2015 had been treated
with 10 × 4 Gy and some dogs after May 2015 were treated with
20 × 2.5 Gy, comparison of survival analysis for “as treated” with
“intention to treat” and “per protocol” regimes showed only minor dis-
crepancy. However, under the assumption of “same risk” (probability
estimates of toxicosis, eg, NTCP), one had to assume less tumor
control and hence we had to leave the choice of protocol to the
owners. The second statistical limitation was the relatively small sam-
ple size could limit power of statistical analyses, especially in the low
frequency of occurrence of expected late toxicosis and survival
FIGURE 3 Proportion alive for all dogs. Censor marks: For OS, all
deaths were considered events and dogs that were still alive at the
time of data evaluation or lost to follow-up were censored. The
dotted lines mark 1 and 2 years
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analysis. The 3rd statistical limitation has a large impact on the struc-
ture of statistical models. Because of the sample size, adjusting for
possible confounders was hardly possible and only univariate models
were considered.
A further limitation of the study was the absence of histological
confirmation of the origin of the tumor in the majority of the dogs.
Diagnostic imaging represents a well-established modality for tumor
diagnosis. Intracranial neoplasia can quite reliably be differentiated
from non-neoplastic diseases.10,11,14–17 Nevertheless, accuracy for
distinction between different tumor types with standard magnetic res-
onance imaging dropped to 70% in 1 study, making it difficult to rely
on statistical differences between tumor types when no histology is
available.16 In addition the presumed tumor types were not evenly
distributed between the 2 groups, causing a possible bias. Some
authors have hypothesized that pituitary tumors treated with radia-
tion have a more favorable outcome compared to tumors of different
histologic origin. The assumption that any of the possible histotypes
in dogs with intracranial tumors and having resulting signs of neuro-
logic disease have a different outcome upon treatment has not been
shown to date.1–3,8,32 In our study, we showed a significantly inferior
outcome in terms of PFI for dogs with diagnosed glial tumors com-
pared to meningioma (P = .001), but no superior outcome for pituitary
gland tumors. Another finding was the shorter PFI for dogs with
severe signs of neurologic disease (P = .005), which had not been
shown in similar reports.1–3 A further limitation of the study results
from challenges encountered in measuring tumor size on CT and MRI
in 2 cases. One, comparing an MRI and a CT where the high concen-
tration of fluid surrounding the tumor made the interpretation of the
measurements difficult, the other showing stable tumor volume in a
dog with stable signs of neurologic disease where we therefore
assumed radiation to have had a positive effect.
In conclusion, the outcome, as well as the low occurrence of
adverse events in dogs irradiated with this moderately hypofractio-
nated protocol of 10 × 4 Gy for their brain tumors can be summarized
as favorable. This shorter and hence less cost intense protocol
provided an improved or even normal quality of life to the vast major-
ity of dogs for a remarkable time span. When escalating the doses
with this moderately hypofractionated protocol as a future route to
improve local tumor control, correct positioning of the dogs, and cor-
rect target localization with image guidance as well as uniform delin-
eation of OAR and target volumes must continuously be adhered
to. In parallel to local control, potential late toxicoses resulting from
lesser-fractioned protocols must also remain an important focus for
the future.
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